Takeda’s Soticlestat Fails In Seizure Trials

 
• By Jessica Merrill

Two Phase III studies testing soticlestat, licensed from Ovid, in Dravet and Lennox-Gastaut syndromes failed to meet their primary endpoints on improvement in seizure frequency.

Missed target
Two of Takeda's Phase III studies missed the primary endpoint • Source: Shutterstock

More from Clinical Trials

More from R&D